These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease. Kendall TJ; Jimenez-Ramos M; Turner F; Ramachandran P; Minnier J; McColgan MD; Alam M; Ellis H; Dunbar DR; Kohnen G; Konanahalli P; Oien KA; Bandiera L; Menolascina F; Juncker-Jensen A; Alexander D; Mayor C; Guha IN; Fallowfield JA Nat Med; 2023 Nov; 29(11):2939-2953. PubMed ID: 37903863 [TBL] [Abstract][Full Text] [Related]
4. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Loomba R; Wong VW Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279 [TBL] [Abstract][Full Text] [Related]
5. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma. Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295 [TBL] [Abstract][Full Text] [Related]
6. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease. Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279 [TBL] [Abstract][Full Text] [Related]
7. Roles of immune dysregulation in MASLD. Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736 [TBL] [Abstract][Full Text] [Related]
8. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339 [TBL] [Abstract][Full Text] [Related]
9. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions. Li M; Larsen FT; van den Heuvel MC; Gier K; Gorter AR; Oosterhuis D; Bijzet J; de Meijer VE; Ravnskjaer K; Nagelkerke A; Olinga P Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474754 [TBL] [Abstract][Full Text] [Related]
10. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers. Zhang X; Li X; Xiong X Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102230. PubMed ID: 37931846 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease. He QJ; Li YF; Zhao LT; Lin CT; Yu CY; Wang D World J Gastroenterol; 2024 Feb; 30(7):652-662. PubMed ID: 38515956 [TBL] [Abstract][Full Text] [Related]
12. Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease? Tulone A; Pennisi G; Ciccioli C; Infantino G; La Mantia C; Cannella R; Mercurio F; Petta S United European Gastroenterol J; 2024 Jun; 12(5):638-648. PubMed ID: 38659291 [TBL] [Abstract][Full Text] [Related]
13. Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression. Oh S; Baek YH; Jung S; Yoon S; Kang B; Han SH; Park G; Ko JY; Han SY; Jeong JS; Cho JH; Roh YH; Lee SW; Choi GB; Lee YS; Kim W; Seong RH; Park JH; Lee YS; Yoo KH Clin Mol Hepatol; 2024 Apr; 30(2):247-262. PubMed ID: 38281815 [TBL] [Abstract][Full Text] [Related]
14. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project. Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Wild-Type and High-risk PNPLA3 variants in a Human Biomimetic Liver Microphysiology System for Metabolic Dysfunction-associated Steatotic Liver Disease Precision Therapy. Xia M; Varmazyad M; Palacin IP; Gavlock DC; Debiasio R; LaRocca G; Reese C; Florentino R; Faccioli LAP; Brown JA; Vernetti LA; Schurdak ME; Stern AM; Gough A; Behari J; Soto-Gutierrez A; Taylor DL; Miedel M bioRxiv; 2024 May; ():. PubMed ID: 38712213 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma. Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077 [TBL] [Abstract][Full Text] [Related]
18. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A; Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202 [TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)]. Canivet CM; Faure S Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295 [TBL] [Abstract][Full Text] [Related]
20. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Zhao S; Guo Y; Yin X Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]